You just read:

Frost & Sullivan Commends Paras Biopharmaceuticals' Comprehensive Technologies and Biologics Portfolio that Economically and Efficiently Addresses Global Affordable Healthcare Issues

News provided by

Frost & Sullivan

11 Dec, 2014, 08:00 GMT